Skip to main content
    S

    Sonoma Pharmaceuticals Inc (SNOA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.84
    -0.04 (-4.56%)

    Market Cap: $5.52M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Sonoma Pharmaceuticals Inc (SNOA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Sonoma Pharmaceuticals (SNOA) has a market cap of $5.52M and an enterprise value of $965.10K. Its share count is up 198.24% from a year earlier. It holds $4.55M more cash than debt, 82.51% of its market cap.

    Total Valuation

    Enterprise value is 82.51% below the market cap, as cash exceeds debt.

    Market Cap$5.52M
    Enterprise Value$965.10K
    Latest price (Nov 17, 2026)$0.84

    Key Dates

    The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 8, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndMarch

    Share Statistics

    The share count rose 27.64% in the quarter ended Sep 30, 2026 and grew 117.89% a year over 2 years.

    Shares Outstanding4.91M
    Shares Change (YoY)+198.24%
    Shares Change (QoQ)+27.64%
    Share Count Growth (2Y CAGR)+117.89%

    Valuation Ratios

    Sales and book value multiples are 0.2x and 0.6x. Its year-end P/S ranged from 0.2x to 17.1x from 2019 to 2025.

    P/S Ratio0.2x
    Forward P/S0.2x
    P/B Ratio0.6x

    Valuation history and multiples

    Price Statistics

    The stock is down 75.58% over 52 weeks and trades 28.81% below its 50-day average.

    Beta (1Y)1.43
    52-Week Change-75.58%
    1-Month Change-24.99%
    3-Month Change-38.23%
    6-Month Change-16.82%
    5-Year Change-99.05%
    10-Year Change-99.85%
    Total Return (1Y)-75.58%
    Total Return (3Y CAGR)-35.88%
    Total Return (5Y CAGR)-62.17%
    Max Drawdown (1Y)-77.89%
    Max Drawdown (3Y)-90.16%
    Sharpe Ratio (1Y)-1.79
    Correlation with SPY (1Y)0.24
    50-Day Average$1.18
    200-Day Average$1.57
    52-Week Range$0.80 to $3.95
    RSI (14 Days)29.2
    Average Volume (20 Days)87.01K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.48x current liabilities, and total debt is 0.01x shareholder equity.

    Current Ratio3.48x
    Quick Ratio2.68x
    Debt / Equity0.01x

    Returns and Efficiency

    Return on invested capital is -20.90% over the last 12 months, against a 5-year average of -95.72%.

    Return on Equity (ROE)-27.15%
    Return on Assets (ROA)-10.50%
    Return on Invested Capital (ROIC)-20.90%
    Return on Capital Employed (ROCE)-10.99%
    ROE (5Y Average)-76.56%
    ROA (5Y Average)-27.90%
    ROIC (5Y Average)-95.72%
    Asset Turnover1.52x
    Inventory Turnover3.91x
    Receivables Turnover6.95x
    Cash Conversion Cycle31 days

    Scores

    SNOA has an Altman Z-Score of -14.38, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-14.38
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $23.49M over the last 12 months is up 38.69% from the 12 months before.

    Revenue$23.49M
    Revenue Growth (YoY)+38.69%
    Gross Profit$9.21M
    Operating Income-$779.00K
    Pretax Income-$1.39M
    Net Income-$1.80M
    EBIT-$1.39M
    Reported EPS (TTM)-$0.52

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 38.65% of the $17.10M in total assets.

    Cash and Equivalents$4.61M
    Total Debt$57.00K
    Net Cash$4.55M
    Net Cash Per Share$0.93
    Working Capital$10.93M
    Shareholder Equity$6.61M
    Book Value Per Share$1.35
    Total Assets$17.10M
    Total Liabilities$10.49M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $120.00K of capital spending, operating cash flow left -$2.79M of free cash flow.

    Operating Cash Flow-$2.67M
    Capital Expenditures$120.00K
    Free Cash Flow-$2.79M
    FCF Per Share-$0.58
    Depreciation and Amortization$129.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -3.32%, against a 5-year average of -31.31%.

    Gross Margin39.23%
    Operating Margin-3.32%
    Pretax Margin-5.93%
    Net Margin-7.65%
    EBIT Margin-5.93%
    FCF Margin-11.87%
    Gross Margin (5Y Average)35.77%
    Operating Margin (5Y Average)-31.31%
    Net Margin (5Y Average)-31.50%

    Growth

    Revenue grew 13.74% a year over 3 years.

    Revenue Growth (3Y CAGR)+13.74%
    Revenue Growth (5Y CAGR)+0.95%
    Book Value Per Share Growth (2Y CAGR)-52.77%
    Tangible Book Per Share Growth (2Y CAGR)-52.77%

    Revenue and profit by year

    Dividends and Yields

    SNOA does not pay a dividend. Its free cash flow yield is -67.60%.

    FCF Yield-67.60%
    Buyback Yield-103.66%
    Shareholder Yield-103.66%

    Stock Splits

    The last split was a 1-for-20 reverse split on Aug 30, 2024.

    Last Split DateAug 30, 2024
    Split TypeReverse split
    Split Ratio1:20

    Peer Position

    Against 5 similar companies, SNOA has the lowest P/S.

    P/S Ratio0.2x vs 1.6x median
    ROIC-20.90% vs -61.17% median
    Revenue Growth (Trailing 4 Quarters, YoY)+38.69% vs +2.39% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 22.44% a year over the next fiscal year.

    Revenue Growth Forecast (1Y CAGR)+22.44%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SNOA

    What is SNOA's market cap?

    Sonoma Pharmaceuticals has a market cap of $5.52M. Its enterprise value, which adds debt and subtracts cash, is $965.10K.

    How many shares of SNOA are outstanding?

    Sonoma Pharmaceuticals has 4.91M shares outstanding. The count is up 198.24% from a year earlier.

    Does SNOA pay a dividend?

    No. Sonoma Pharmaceuticals does not pay a dividend.

    How much debt does SNOA have?

    Sonoma Pharmaceuticals has $57.00K of total debt and $4.61M of cash and equivalents, a net cash position of $4.55M.